Malecare Prostate Cancer Support Group

Malecare

About Malecare

This author has not yet filled in any details.
So far Malecare has created 608 blog entries.

Towards An Understanding Of The Possible Future Role Of Combining Chemotherapy With Immunotherapy – On The Horizon

There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled "Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy."  The study was conducted at the University of California, San Diego. Prostate cancers [...]

By |2017-10-19T10:47:20-04:00May 29th, 2015|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials & Research, Combination Therapy, Immunosuppressive B cells, oxaliplatin, Research, Uncategorized|0 Comments
Read More

Evaluating The Side Effects Of Docetaxel (Taxotere) vs Cabazitaxel (Jevtana)

Many men express great hesitation to move to chemotherapy with both docetaxel (taxotere) and cabazitaxel (Jevtana) because of the side effects which can include alopecia (hair loss), nail changes, neuropathy, and dysgeusia (a distortion of the sense of taste). A group of researchers hypothesized that the adverse side effects (AE) of these two chemotherapy drugs, [...]

By |2020-02-04T11:37:16-05:00May 26th, 2015|Advanced Prostate Cancer, Cabazitaxel, Chemotherapy, docetaxel, Jevtana, peripheral neuropathy, Side Effects, taxotere, Uncategorized|1 Comment
Read More

The PREVAIL Trial Shows That Enzalutamide Not Only Increases Overall Survival Over Placebo, It Also Delays the Onset Of The First Skeletal Event

Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]

By |2020-02-04T11:37:24-05:00May 22nd, 2015|Advanced Prostate Cancer, Bones and Prostate Cancer, Clinical Trials, enzalutamide, Quality of Life, survival, Uncategorized, Xtandi|0 Comments
Read More

SEER PSA Data Is Flawed and Removed By the NCI – What Are the Implications for the Flawed USPTF PSA Debacle?

I am not sure what to do with this information, but it certainly could be described as a rather large elephant in the room. We all are very familiar with the prostate cancer PSA test controversy brought on by the United States Preventive Task Force (USPTF). To quickly review the issue, the USPTF developed a [...]

By |2017-10-19T10:47:21-04:00May 20th, 2015|Advanced Prostate Cancer, General Information, PSA, Research, Screening, Uncategorized, USPTF|0 Comments
Read More

The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi

At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]

By |2021-02-22T10:05:38-05:00May 19th, 2015|abiraterone acetate, Advanced Prostate Cancer, AUA, biomarkers, CTCs, enzalutamide, Research, Uncategorized, Xtandi, Zytiga|1 Comment
Read More
Go to Top